MagForce AG Announces Positive Results Of 2015 Annual General Meeting

• The Annual General Meeting approves all agenda items with a clear majority

• Executive Board and Supervisory Board have been discharged

Berlin, Germany, August 18, 2015 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting in Berlin today. The Annual General Meeting approved all resolution items with a clear majority.

The CEO and Chairman of the Management Board, Dr. Ben J. Lipps, explained the current operational developments in detail and provided an overview of the 2014 fiscal year, as well as an outlook for the current year. Subsequently, he updated the status of his strategic five-year plan.

The Management Board and Supervisory Board were pleased by the positive election results.

The Management Board presentation is available on the Company's website at www.magforce.de/en/presse-investoren/hauptversammlung.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Help employers find you! Check out all the jobs and post your resume.

Back to news